These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29606312)

  • 1. Transport Barriers and Oncophysics in Cancer Treatment.
    Nizzero S; Ziemys A; Ferrari M
    Trends Cancer; 2018 Apr; 4(4):277-280. PubMed ID: 29606312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transport Oncophysics in silico, in vitro, and in vivo. Preface.
    Koay EJ; Ferrari M
    Phys Biol; 2014 Nov; 11(6):060201. PubMed ID: 25426742
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting Biophysical Cues: a Niche Approach to Study, Diagnose, and Treat Cancer.
    Zhang SX; Liu L; Zhao W
    Trends Cancer; 2018 Apr; 4(4):268-271. PubMed ID: 29606309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why I'm Holding onto Hope for Nano in Oncology.
    Allen C
    Mol Pharm; 2016 Aug; 13(8):2603-4. PubMed ID: 27404330
    [No Abstract]   [Full Text] [Related]  

  • 5. Barriers to drug delivery in interventional oncology.
    Sheth RA; Hesketh R; Kong DS; Wicky S; Oklu R
    J Vasc Interv Radiol; 2013 Aug; 24(8):1201-7. PubMed ID: 23735316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside.
    Stylianopoulos T; Munn LL; Jain RK
    Trends Cancer; 2018 Apr; 4(4):292-319. PubMed ID: 29606314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncology biomarkers--second annual GTCbio conference. Biomarkers for disease detection and therapeutics monitoring. 19-20 January 2009, Miami, FL, USA.
    Scholler N
    IDrugs; 2009 Apr; 12(4):207-10. PubMed ID: 19350459
    [No Abstract]   [Full Text] [Related]  

  • 9. Modulating the tumor microenvironment with new therapeutic nanoparticles: A promising paradigm for tumor treatment.
    Zhang Y; Ho SH; Li B; Nie G; Li S
    Med Res Rev; 2020 May; 40(3):1084-1102. PubMed ID: 31709590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmable nanomedicine: synergistic and sequential drug delivery systems.
    Pacardo DB; Ligler FS; Gu Z
    Nanoscale; 2015 Feb; 7(8):3381-91. PubMed ID: 25631684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
    Danhier F
    J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frontiers in cancer nanomedicine: directing mass transport through biological barriers.
    Ferrari M
    Trends Biotechnol; 2010 Apr; 28(4):181-8. PubMed ID: 20079548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomedicine in management of hepatocellular carcinoma: Challenges and opportunities.
    Mohamed NK; Hamad MA; Hafez MZ; Wooley KL; Elsabahy M
    Int J Cancer; 2017 Apr; 140(7):1475-1484. PubMed ID: 27861850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanomedicine: the promise and challenges in cancer chemotherapy.
    Naguib YW; Cui Z
    Adv Exp Med Biol; 2014; 811():207-33. PubMed ID: 24683034
    [No Abstract]   [Full Text] [Related]  

  • 16. Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications.
    Ranganathan R; Madanmohan S; Kesavan A; Baskar G; Krishnamoorthy YR; Santosham R; Ponraju D; Rayala SK; Venkatraman G
    Int J Nanomedicine; 2012; 7():1043-60. PubMed ID: 22403487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physical oncology: New targets for nanomedicine.
    Nicolas-Boluda A; Silva AKA; Fournel S; Gazeau F
    Biomaterials; 2018 Jan; 150():87-99. PubMed ID: 29035739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Strategies in Cancer Nanomedicine.
    Tong R; Kohane DS
    Annu Rev Pharmacol Toxicol; 2016; 56():41-57. PubMed ID: 26514197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanooncology: the future of cancer diagnosis and therapy.
    Thakor AS; Gambhir SS
    CA Cancer J Clin; 2013; 63(6):395-418. PubMed ID: 24114523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.